Skip to main content

PBL Licenses Quansys Multiplex Arrays

NEW YORK (GenomeWeb News) – PBL InterferonSource has licensed international and limited US rights to sells Quansys Biosciences' Q-Plex multiplex array kits and related products, under an agreement announced by the firms today.

PBL will offer the kits in combination with its own interferon reagents, enabling researchers to examine the relationship of multiple interferons and cytokines simultaneously. The combination will allow researchers to assess cytokine profiles at various points throughout the course of disease, correlate alterations in cytokine profiles with patient responses to therapies, and determine off-target effects of drugs, the firms said.

"This unique blend of cost-effective technology and interferon content should prove extremely beneficial to scientists developing the next generation of autoimmunity, viral, and cancer therapeutics," Robert Pestka, president and CEO of PBL InterferonSource, said in a statement.

Financial and other terms of the license were not disclosed.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.